EIDD-2749

Research use only, not for human use.

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.

EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.

EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP.EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures.EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC50 169 mM), resulting in a high SI (SI = EC50/CC50) of ≥1877.EIDD-2749 inhibits SARS-CoV-2 with an EC50 value of 0.2-0.6 M.EIDD-2749 has an EC50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC50 of 380 μM, and stability in human plasma.

EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner.EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo.Animal Model:Balb/cJ mice (RSV infection model).Dosage:0.2, 1, 5 mg/kg Administration:Oral administration; single daily for 4 days Result:Resulted in a statistically significant reduction in lung virus load.

——

Immunology/Inflammation

Antiviral

Antiviral | SARS-CoV

——

——

1613589-24-4

262.19

C9H11FN2O6

>98% (HPLC)

In Vitro:?H2O : 62.5 mg/mL (238.38 mM; Ultrasonic) DMSO : 25 mg/mL (95.35 mM; Ultrasonic )

O[C@H]1[C@@H](O[C@@](CO)(F)[C@H]1O)N2C(=O)NC(=O)C=C2

——

(-20℃)

With Ice Pack

≥ 2 years